Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) — Stock Price

CN¥39.73 CNY
▲ 0.43% today

Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) is currently trading at CN¥39.73 CNY, up 0.43% today. Over the past 52 weeks, shares have ranged between CN¥35.31 and CN¥56.43. This page tracks Tibet Rhodiola Pharmaceutical Holding Co's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Tibet Rhodiola Pharmaceutical Holding Co market capitalisation.

Tibet Rhodiola Pharmaceutical Holding Co (600211) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Tibet Rhodiola Pharmaceutical Holding Co's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.

Tibet Rhodiola Pharmaceutical Holding Co Income Statement — Revenue, Profit & Earnings by Year

Tibet Rhodiola Pharmaceutical Holding Co's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CN¥2.95 Billion CN¥2.81 Billion CN¥3.13 Billion CN¥2.55 Billion CN¥2.14 Billion
Cost of Revenue CN¥213.32 Million CN¥162.10 Million CN¥158.67 Million CN¥204.74 Million CN¥225.80 Million
Gross Profit CN¥2.74 Billion CN¥2.64 Billion CN¥2.98 Billion CN¥2.35 Billion CN¥1.91 Billion
Research & Development CN¥62.17 Million CN¥28.94 Million CN¥17.35 Million CN¥88.13 Million CN¥60.86 Million
SG&A CN¥46.77 Million CN¥122.14 Million CN¥124.00 Million CN¥132.47 Million CN¥99.46 Million
Total Operating Expenses CN¥1.81 Billion CN¥1.48 Billion CN¥2.08 Billion CN¥1.89 Billion CN¥1.66 Billion
Operating Income CN¥924.70 Million CN¥1.16 Billion CN¥899.09 Million CN¥464.65 Million CN¥256.80 Million
EBITDA CN¥1.00 Billion CN¥1.24 Billion CN¥978.19 Million CN¥547.41 Million CN¥340.63 Million
EBIT CN¥924.70 Million CN¥1.16 Billion CN¥910.15 Million CN¥478.17 Million CN¥259.18 Million
Interest Expense CN¥12.75 Million CN¥9.29 Million CN¥11.95 Million CN¥14.78 Million CN¥4.33 Million
Income Before Tax CN¥1.04 Billion CN¥1.15 Billion CN¥898.19 Million CN¥463.39 Million CN¥254.85 Million
Income Tax Expense CN¥123.64 Million CN¥95.01 Million CN¥87.95 Million CN¥88.08 Million CN¥41.82 Million
Net Income CN¥937.93 Million CN¥1.05 Billion CN¥800.91 Million CN¥369.84 Million CN¥208.94 Million

Tibet Rhodiola Pharmaceutical Holding Co Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Tibet Rhodiola Pharmaceutical Holding Co's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CN¥6.27 Billion CN¥4.75 Billion CN¥4.59 Billion CN¥4.10 Billion CN¥3.80 Billion
Total Current Assets CN¥4.64 Billion CN¥3.57 Billion CN¥3.40 Billion CN¥2.71 Billion CN¥2.18 Billion
Cash & Equivalents — — — — —
Short-term Investments CN¥1.78 Billion CN¥976.62 Million CN¥515.34 Million CN¥792.49 Million CN¥537.87 Million
Net Receivables CN¥989.61 Million CN¥744.67 Million CN¥856.71 Million CN¥625.68 Million CN¥632.32 Million
Inventory CN¥181.27 Million CN¥134.19 Million CN¥111.44 Million CN¥99.95 Million CN¥137.32 Million
Property, Plant & Equipment — — — CN¥551.38 Million CN¥764.54 Million
Goodwill CN¥84.01 Million CN¥8.88 Million CN¥8.88 Million CN¥8.88 Million CN¥8.88 Million
Total Liabilities CN¥2.10 Billion CN¥795.23 Million CN¥1.21 Billion CN¥1.07 Billion CN¥1.16 Billion
Total Current Liabilities CN¥1.64 Billion CN¥766.57 Million CN¥1.18 Billion CN¥1.03 Billion CN¥1.11 Billion
Long-term Debt — — — — —
Net Debt CN¥-826.21 Million CN¥-1.38 Billion CN¥-1.36 Billion CN¥-651.58 Million CN¥-225.76 Million
Total Stockholder Equity CN¥3.80 Billion CN¥3.92 Billion CN¥3.34 Billion CN¥3.01 Billion CN¥2.63 Billion
Retained Earnings CN¥2.50 Billion CN¥2.17 Billion CN¥1.65 Billion CN¥1.33 Billion CN¥1.04 Billion

Tibet Rhodiola Pharmaceutical Holding Co Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Tibet Rhodiola Pharmaceutical Holding Co generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CN¥1.03 Billion CN¥994.79 Million CN¥1.08 Billion CN¥837.38 Million CN¥366.53 Million
Capital Expenditures CN¥15.96 Million CN¥37.60 Million CN¥21.69 Million CN¥101.96 Million CN¥425.58 Million
Free Cash Flow CN¥1.01 Billion CN¥957.19 Million CN¥1.04 Billion CN¥735.41 Million CN¥-59.05 Million
Investing Cash Flow CN¥-611.04 Million CN¥354.49 Million CN¥-848.39 Million CN¥-561.25 Million CN¥-740.80 Million
Financing Cash Flow CN¥-122.62 Million CN¥-732.99 Million CN¥-485.89 Million CN¥-145.37 Million CN¥376.67 Million
Dividends Paid CN¥617.51 Million CN¥504.05 Million CN¥482.98 Million CN¥98.18 Million CN¥126.45 Million
Stock-Based Compensation — — — — —
Depreciation CN¥78.72 Million CN¥74.16 Million CN¥61.74 Million CN¥69.24 Million CN¥81.45 Million
Change in Cash CN¥357.37 Million CN¥623.72 Million CN¥-245.11 Million CN¥170.87 Million CN¥-12.02 Million

Tibet Rhodiola Pharmaceutical Holding Co Earnings History — EPS Actual vs. Analyst Estimates

Track Tibet Rhodiola Pharmaceutical Holding Co's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Apr 16, 2025 — — —
Apr 27, 2023 1.22 — —
Mar 10, 2023 -0.29 — —
Oct 27, 2022 0.73 — —
Aug 18, 2022 0.35 — —
Apr 26, 2022 0.70 — —
Mar 11, 2022 -0.84 — —
Oct 27, 2021 0.49 — —